PRLD stock news · Prelude Therapeutics
Get alerts for PRLD
Follow Prelude Therapeutics (PRLD) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PRLDFree on the App Store and Google Play, or on the web.
Prelude Therapeutics shared its third quarter 2026 results, showing a solid cash position and progress in its studies.
Good for PRLDPrelude reported $142.7 million in cash, expected to fund operations into the second quarter of 2028, and a Lilly study agreement. This is a positive update for Prelude.
Prelude Therapeutics says the FDA has approved its first study for a new breast cancer drug.
Good for PRLDThe FDA cleared Prelude's IND to start a Phase 1 study of PRT13722; this is positive for Prelude.